STEAP1 CART / Promicell Therap, Fred Hutchinson Cancer Center - LARVOL DELTA

Collagen-binding IL-12-armoured STEAP1 CAR-T cells reduce toxicity and treat prostate cancer in mouse models. (PubMed, Nat Biomed Eng) - "In addition, human CBD-IL-12-armoured CAR-T cells showed potent anti-tumour efficacy in a 22Rv1 xenograft while reducing circulating IL-12 levels compared with unmodified IL-12-armoured CAR-T cells. CBD fusion to potent payloads for CAR-T therapy may remove obstacles to their clinical translation towards elimination of solid tumours."

Journal • Preclinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • IFNG • IL12A • STEAP1

Engineering Next-Generation STEAP1 CAR T Cells: Development and Optimization for Enhanced Anti-Tumor Efficacy in Prostate Cancer (PCF 2024) - "Our research advances STEAP1-BBζ CAR-T cell therapy by addressing challenges such as antigen escape and functional exhaustion. Optimized PSMA CAR T cells exhibit enhanced anti-tumor efficacy, supporting the development of dual-targeting PSMA-STEAP1 CAR T cells. Additionally, our in vitro model and CRISPR screen identified genetic modifications that enhance metabolic fitness and CAR T cell activity."

CAR T-Cell Therapy • Clinical • IO biomarker • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Hematological Malignancies • Oncology • Prostate Cancer • Solid Tumor • CD4 • CD8 • IFNG • PSCA • STEAP1

Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - P1/2 | N=48 | Not yet recruiting | Sponsor: Fred Hutchinson Cancer Center | Initiation date: Sep 2024 ➔ Dec 2024

Metastases • Trial initiation date • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Metastatic Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - P1/2 | N=48 | Recruiting | Sponsor: Fred Hutchinson Cancer Center | Not yet recruiting ➔ Recruiting

Enrollment open • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - P1/2 | N=48 | Not yet recruiting | Sponsor: Fred Hutchinson Cancer Center | Initiation date: May 2024 ➔ Sep 2024

Metastases • Trial initiation date • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Metastatic Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - P1/2 | N=48 | Not yet recruiting | Sponsor: Fred Hutchinson Cancer Center

New P1/2 trial • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Metastatic Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor